Revvity Inc
0KHE.L
$101.63 -1.52%
Exchange: LSE | Sector: Healthcare | Industry: Medical Diagnostics Research
Q1 2025
Published: May 6, 2025

Earnings Highlights

  • Revenue of $664.76M down 2.8% year-over-year
  • EPS of $0.34 decreased by 54.9% from previous year
  • Gross margin of 49.2%
  • Net income of 41.44M
  • "" -
0KHE.L
Company 0KHE.L

Executive Summary

Revvity delivered a profitable Q1 2025, but topline momentum cooled against prior year and the prior quarter. Revenue totaled $664.76 million, down 2.82% year-over-year and 8.86% quarter-over-quarter, while gross margin remained robust at 49.2% (gross profit $327.25 million). The company generated $128.16 million of cash from operations and reported free cash flow of $112.17 million, supporting a strong liquidity position as of March 30, 2025. Net income was $41.44 million with an EPS of $0.345, reflecting disciplined cost management in an environment of revenue headwinds. EBITDA stood at $172.77 million with an EBITDA margin of about 26.0%, underscoring earnings quality despite top-line declines.

Key Performance Indicators

Revenue
Decreasing
664.76M
QoQ: -8.86% | YoY: -2.82%
Gross Profit
Decreasing
327.25M
49.23% margin
QoQ: -9.02% | YoY: -14.96%
Operating Income
Decreasing
87.97M
QoQ: -33.50% | YoY: -14.26%
Net Income
Decreasing
41.44M
QoQ: -56.40% | YoY: -55.90%
EPS
Decreasing
0.34
QoQ: -55.78% | YoY: -54.92%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q3 2025 698.95 0.40 -4.2% View
Q2 2025 720.28 0.47 +5.3% View
Q1 2025 664.76 0.34 -2.8% View
Q4 2024 729.37 0.78 +5.5% View